Table S1, Table S2 from Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin As Potential Biomarkers of Clinical Activity Didier Meulendijks , Wolfgang Jacob , Emile E. Voest , Morten Mau-Sorensen , Maria Martinez-Garcia , Alvaro Taus , Tania Fleitas , Andres Cervantes , Martijn P. Lolkema , Marlies H.G. Langenberg , Maja J. De Jonge , Stefan Sleijfer , Ji-Youn Han , Antonio Calles , Enriqueta Felip , Sang-We Kim , Jan H.M. Schellens , Sabine Wilson , Marlene Thomas , Maurizio Ceppi , Georgina Meneses-Lorente , Ian James , Suzana Vega-Harring , Rajiv Dua , Maitram Nguyen , Lori Steiner , Celine Adessi , Francesca Michielin , Birgit Bossenmaier , Martin Weisser , Ulrik N. Lassen openalex（2023）
关键词
Biomarkers for Immunotherapy, Tumor Microenvironment
AI 理解论文
溯源树
样例
